高尿酸血症肾病 中国就医指南

Uric Acid Nephropathy (UAN) is a form of chronic kidney injury caused by the deposition of monosodium urate crystals or uric acid crystals in the renal parenchyma and tubular lumens, leading to inflammation, interstitial fibrosis, tubular atrophy, and progressive decline in glomerular filtration rate. It encompasses both acute uric acid nephropathy—typically triggered by rapid tumor lysis or excessive purine catabolism—and chronic uric acid nephropathy, which develops insidiously over years due to persistent hyperuricemia (>6.8 mg/dL), often in the context of metabolic syndrome, obesity, hypertension, or chronic kidney disease (CKD). Pathogenesis involves multiple interconnected mechanisms: uric acid–induced endothelial dysfunction, activation of the renin-angiotensin–aldosterone system (RAAS), oxidative stress, NLRP3 inflammasome activation, and direct crystal-mediated tubulointerstitial injury. Hyperuricemia promotes vasoconstriction, reduces nitric oxide bioavailability, and stimulates pro-fibrotic cytokine release (e.g., TGF-β), accelerating renal structural damage. Epidemiologically, UAN affects an estimated 5–10% of adults with sustained hyperuricemia, with higher prevalence among males aged 40–65 and individuals with gout, CKD stage 3+, diabetes mellitus, or cardiovascular disease. In China, national surveys indicate rising incidence parallel to urbanization and dietary shifts—approximately 13.3% of Chinese adults have hyperuricemia, and among those with eGFR <60 mL/min/1.73m², up to 22% show histopathologic evidence consistent with uric acid–related nephropathy. Key modifiable risk factors include high-purine diets (red meat, shellfish, alcohol—especially beer), fructose-sweetened beverages, dehydration, diuretic use (e.g., thiazides), and chronic lead exposure. Non-modifiable risks include genetic variants in urate transporters (e.g., SLC2A9, ABCG2), male sex, and aging. Untreated UAN significantly impairs quality of life: patients commonly experience fatigue, nocturia, reduced exercise tolerance, anxiety about dialysis progression, and socioeconomic burden from recurrent clinic visits, medication adherence challenges, and work absenteeism. As renal function declines, comorbidities such as hypertension and anemia worsen, further diminishing physical functioning and mental well-being. Early diagnosis—via serum uric acid, 24-hour urinary uric acid excretion, fractional excretion of uric acid (FEUA), renal ultrasound (showing increased echogenicity), and occasionally kidney biopsy—is critical to prevent irreversible fibrosis. Without intervention, UAN may progress to end-stage kidney disease requiring dialysis or transplantation.

# 高尿酸血症肾病治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：eGFR ≥60 mL/min/1.73m²、无痛风石、无急性肾损伤者

• •基础管理：低嘌呤饮食指导+水化+体重管理（免费–200元/次）
• •降尿酸药物：

• •检验监测：血尿酸、肾功能、尿微量白蛋白/肌酐比（180–320元/次）；24h尿尿酸定量（260–450元/次）

二、介入/核心治疗方案

适用人群：顽固性高尿酸血症（血尿酸＞540 μmol/L）、伴进行性eGFR下降（年降幅＞3 mL/min）

• •尿酸酶类药物（拉布立酶/培格洛替酶）：仅用于难治性病例，需住院输注；单疗程（4–8周）费用：28,000–65,000元（含药费、监护、输液反应处理）
• •术前检查（必查）：心超、肝肾功能、G6PD筛查、过敏试验：1,200–2,100元

三、晚期/并发症方案

适用人群：CKD 4–5期、合并痛风肾结石或尿酸性肾病纤维化

• •多学科联合管理（肾内科+风湿免疫科+营养科）：门诊随访套餐（含血透评估、碱化尿液指导、结石干预）：450–980元/次
• •合并尿路梗阻需经皮肾造瘘或输尿管支架置入：12,000–22,000元/次（含DSA引导、耗材、住院）

方案快速选择指南

• •预算有限（＜1,000元/月）：别嘌醇+生活方式干预（首选）
• •中等预算（1,500–5,000元/月）：非布司他+定期监测+营养师随访
• •急进性肾损伤/难治性高尿酸：立即启动尿酸酶评估，单疗程预算≥3万元
• •CKD 4期以上：优先转诊至肾内科专病门诊制定个体化延缓进展方案